`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`Orange Book: Approved Drug Products
`with Therapeutic Equivalence Evaluations
`
` SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?
`U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=021303&APPL_TYPE=N)
`
` TWEET (HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC
`EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?
`PRODUCT_NO=001&APPL_NO=021303&APPL_TYPE=N)
`
`
`
`EMAIL (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
`EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?
`PRODUCT_NO=001&APPL_NO=021303&APPL_TYPE=N)
`
`Home (default.cfm?resetfields=1) | Back to Product Details
`
`Additional Information about Patents
`
`Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
`Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may
`include drug substance and/or drug product claims that are not indicated in the listing.
`As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug
`substance and the drug product (and is eligible for listing on either basis) is required only to specify that it
`claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book
`patent listing, regardless of when first published, to determine the range of patent claims that may be
`asserted by an NDA holder or patent owner.
`
`Patent and Exclusivity for: N021303
`
`Product 001
`AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE
`SACCHARATE; DEXTROAMPHETAMINE SULFATE (ADDERALL XR 10) CAPSULE, EXTENDED
`RELEASE 2.5MG;2.5MG;2.5MG;2.5MG
`
`Patent Data
`
`https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021303&Appl_type=N
`
`1/2
`
`KVK-TECH EXHIBIT 1021
`
`
`
`8/25/2017
`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`Product
`No
`
`001
`
`001
`
`001
`
`001
`
`001
`
`001
`
`001
`
`001
`
`Patent No
`
`6322819
`
`Patent
`Expiration
`
`Drug
`Substance
`Claim
`
`Drug
`Product
`Claim
`
`Oct 21,
`2018
`
`6322819*PED Apr 21,
`2019
`
`6605300
`
`Oct 21,
`2018
`
`6605300*PED Apr 21,
`2019
`
`RE41148
`
`Oct 21,
`2018
`
`RE41148*PED Apr 21,
`2019
`
`RE42096
`
`Oct 21,
`2018
`
`RE42096*PED Apr 21,
`2019
`
`DP
`
`DP
`
`Delist
`Requested
`
`Patent Use Code
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`(show_code.cfm?
`id=&type=0)
`
`
`
`Exclusivity Data
`
`Product No
`
`Exclusivity Code
`
`Exclusivity Expiration
`
`There is no unexpired exclusivity for this product in the Orange Book database.
`
`View a list of all patent use codes (results_patent.cfm)
`View a list of all exclusivity codes (results_exclusivity.cfm)
`
`https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021303&Appl_type=N
`
`2/2
`
`